BR112016029911A2 - biomarcadores para resposta a inibidores de ezh2 - Google Patents
biomarcadores para resposta a inibidores de ezh2Info
- Publication number
- BR112016029911A2 BR112016029911A2 BR112016029911A BR112016029911A BR112016029911A2 BR 112016029911 A2 BR112016029911 A2 BR 112016029911A2 BR 112016029911 A BR112016029911 A BR 112016029911A BR 112016029911 A BR112016029911 A BR 112016029911A BR 112016029911 A2 BR112016029911 A2 BR 112016029911A2
- Authority
- BR
- Brazil
- Prior art keywords
- cancer
- biomarkers
- bap1
- subject
- ezh2
- Prior art date
Links
- 101150090105 Ezh2 gene Proteins 0.000 title abstract 4
- 239000000090 biomarker Substances 0.000 title abstract 4
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 101150054061 BAP1 gene Proteins 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 230000001093 anti-cancer Effects 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 1
- 239000013643 reference control Substances 0.000 abstract 1
- 230000003827 upregulation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/91005—Transferases (2.) transferring one-carbon groups (2.1)
- G01N2333/91011—Methyltransferases (general) (2.1.1.)
- G01N2333/91017—Methyltransferases (general) (2.1.1.) with definite EC number (2.1.1.-)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7023—(Hyper)proliferation
- G01N2800/7028—Cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
o assunto presentemente descrito diz respeito à utilização de um ou mais biomarcadores para avaliar a probabilidade de um inibidor de ezh2 produzir um efeito anti-câncer num sujeito. é baseado, pelo menos em parte, na conclusão que a perda de bap1 resulta numa regulação positiva da expressão e actividade de ezh2. de acordo com uma variante específica não limitativa, o método compreende a obtenção de uma amostra de câncer de um sujeito e a determinação, na amostra, do nível de expressão de um biomarcador bap1, em que no caso do biomarcador bap1 estar ausente ou ser expresso num nível inferior no câncer em comparação com um nível de controlo de referência, então administrar uma quantidade terapeuticamente eficaz de um inibidor de ezh2 para produzir um efeito anti-câncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462014594P | 2014-06-19 | 2014-06-19 | |
PCT/US2015/036677 WO2015196064A1 (en) | 2014-06-19 | 2015-06-19 | Biomarkers for response to ezh2 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112016029911A2 true BR112016029911A2 (pt) | 2017-10-24 |
Family
ID=54936135
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112016029911A BR112016029911A2 (pt) | 2014-06-19 | 2015-06-19 | biomarcadores para resposta a inibidores de ezh2 |
Country Status (15)
Country | Link |
---|---|
US (1) | US20170138946A1 (pt) |
EP (1) | EP3158086B1 (pt) |
JP (1) | JP6684230B2 (pt) |
KR (1) | KR20170020463A (pt) |
CN (1) | CN106795561B (pt) |
AU (1) | AU2015276899B2 (pt) |
BR (1) | BR112016029911A2 (pt) |
CA (1) | CA2952285A1 (pt) |
EA (1) | EA036889B1 (pt) |
ES (1) | ES2870096T3 (pt) |
IL (1) | IL249443B (pt) |
MX (1) | MX2016017097A (pt) |
SG (2) | SG11201610610YA (pt) |
WO (1) | WO2015196064A1 (pt) |
ZA (1) | ZA201608555B (pt) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2996412A1 (en) | 2015-08-24 | 2017-03-02 | Epizyme, Inc. | Method for treating cancer |
TW201718598A (zh) | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Ezh2抑制劑 |
SG11201806946VA (en) * | 2016-02-16 | 2018-09-27 | Agency Science Tech & Res | Epigenomic profiling reveals the somatic promoter landscape of primary gastric adenocarcinoma |
GB201615842D0 (en) * | 2016-09-16 | 2016-11-02 | Ucl Business Plc | Cell death biomarker |
CN106963765B (zh) * | 2017-03-28 | 2020-04-07 | 上海交通大学医学院附属第九人民医院 | Ezh2抑制剂化合物在制备治疗眼部黑色素瘤的药物中的应用 |
GB201919219D0 (en) | 2019-12-23 | 2020-02-05 | Otsuka Pharma Co Ltd | Cancer biomarkers |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US548257A (en) | 1895-10-22 | Hay rake and loader | ||
US5322770A (en) | 1989-12-22 | 1994-06-21 | Hoffman-Laroche Inc. | Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription |
EP1231282A3 (en) | 1990-12-06 | 2005-05-18 | Affymetrix, Inc. | Methods and compositions for identification of polymers |
US6379897B1 (en) | 2000-11-09 | 2002-04-30 | Nanogen, Inc. | Methods for gene expression monitoring on electronic microarrays |
US6465611B1 (en) | 1997-02-25 | 2002-10-15 | Corixa Corporation | Compounds for immunotherapy of prostate cancer and methods for their use |
US5932422A (en) * | 1997-11-14 | 1999-08-03 | Millennium Pharmaceuticals, Inc. | Modulation of drug resistance via ubiquitin carboxy-terminal hydrolase |
US6218114B1 (en) | 1998-03-27 | 2001-04-17 | Academia Sinica | Methods for detecting differentially expressed genes |
US6004755A (en) | 1998-04-07 | 1999-12-21 | Incyte Pharmaceuticals, Inc. | Quantitative microarray hybridizaton assays |
US6218122B1 (en) | 1998-06-19 | 2001-04-17 | Rosetta Inpharmatics, Inc. | Methods of monitoring disease states and therapies using gene expression profiles |
US6406921B1 (en) | 1998-07-14 | 2002-06-18 | Zyomyx, Incorporated | Protein arrays for high-throughput screening |
US6271002B1 (en) | 1999-10-04 | 2001-08-07 | Rosetta Inpharmatics, Inc. | RNA amplification method |
US7429466B2 (en) | 2000-01-24 | 2008-09-30 | Hypromatrix, Inc | Methods and arrays for detecting biological molecules |
US6618679B2 (en) | 2000-01-28 | 2003-09-09 | Althea Technologies, Inc. | Methods for analysis of gene expression |
WO2002086168A1 (en) | 2001-04-19 | 2002-10-31 | Ciphergen Biosystems, Inc. | Biomolecule characterization using mass spectrometry and affinity tags |
EP1390497A2 (en) | 2001-05-25 | 2004-02-25 | Genset | Human cdnas and proteins and uses thereof |
US7112408B2 (en) | 2001-06-08 | 2006-09-26 | The Brigham And Women's Hospital, Inc. | Detection of ovarian cancer based upon alpha-haptoglobin levels |
US20030013208A1 (en) | 2001-07-13 | 2003-01-16 | Milagen, Inc. | Information enhanced antibody arrays |
WO2003017177A2 (en) | 2001-08-13 | 2003-02-27 | Beyong Genomics, Inc. | Method and system for profiling biological systems |
AU2003213054A1 (en) | 2002-02-20 | 2003-09-09 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF POLYCOMB GROUP PROTEIN EZH2 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US20030215858A1 (en) | 2002-04-08 | 2003-11-20 | Baylor College Of Medicine | Enhanced gene expression system |
AU2003239152A1 (en) | 2002-04-23 | 2003-11-10 | Millipore Corporation | Sample preparation of biological fluids for proteomic applications |
ES2434915T3 (es) | 2005-06-20 | 2013-12-18 | Advanced Cell Diagnostics, Inc. | Detección múltiplex de ácidos nucleicos |
US20110251216A1 (en) | 2010-02-19 | 2011-10-13 | The Regents Of The University Of Michigan | Compositions and methods for inhibiting ezh2 |
HUE028977T2 (en) | 2010-09-10 | 2017-02-28 | Epizyme Inc | A method for determining the suitability of human EZH2 inhibitors during treatment |
US9175331B2 (en) | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
EP2676134A4 (en) * | 2011-02-16 | 2015-04-08 | Sloan Kettering Inst Cancer | BAP1 MUTATION ANALYSIS IN DETERMINING THE EVENT OF, PROGNOSIS AND TREATMENT OF MELANOCYTARY NEOPLASIA |
WO2012144220A1 (en) * | 2011-04-22 | 2012-10-26 | Oncotherapy Science, Inc. | Ezh2 as target gene for cancer therapy and diagnosis |
RU2014117632A (ru) * | 2011-09-30 | 2015-11-10 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | Способы лечения злокачественной опухоли |
CN104540500B (zh) | 2012-03-12 | 2019-02-22 | Epizyme股份有限公司 | 人ezh2抑制剂及其应用方法 |
CA2887243C (en) | 2012-10-15 | 2024-04-09 | Epizyme, Inc. | Methods of treating cancer |
-
2015
- 2015-06-19 SG SG11201610610YA patent/SG11201610610YA/en unknown
- 2015-06-19 CA CA2952285A patent/CA2952285A1/en not_active Abandoned
- 2015-06-19 CN CN201580044280.9A patent/CN106795561B/zh not_active Expired - Fee Related
- 2015-06-19 EA EA201692497A patent/EA036889B1/ru unknown
- 2015-06-19 AU AU2015276899A patent/AU2015276899B2/en not_active Ceased
- 2015-06-19 SG SG10202007972SA patent/SG10202007972SA/en unknown
- 2015-06-19 WO PCT/US2015/036677 patent/WO2015196064A1/en active Application Filing
- 2015-06-19 BR BR112016029911A patent/BR112016029911A2/pt not_active Application Discontinuation
- 2015-06-19 ES ES15809484T patent/ES2870096T3/es active Active
- 2015-06-19 EP EP15809484.7A patent/EP3158086B1/en active Active
- 2015-06-19 JP JP2016573588A patent/JP6684230B2/ja not_active Expired - Fee Related
- 2015-06-19 KR KR1020177001353A patent/KR20170020463A/ko active IP Right Grant
- 2015-06-19 MX MX2016017097A patent/MX2016017097A/es unknown
-
2016
- 2016-12-07 IL IL249443A patent/IL249443B/en unknown
- 2016-12-12 ZA ZA2016/08555A patent/ZA201608555B/en unknown
- 2016-12-15 US US15/380,807 patent/US20170138946A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN106795561B (zh) | 2021-04-16 |
EP3158086B1 (en) | 2021-03-24 |
CN106795561A (zh) | 2017-05-31 |
KR20170020463A (ko) | 2017-02-22 |
SG10202007972SA (en) | 2020-10-29 |
MX2016017097A (es) | 2017-05-01 |
EP3158086A1 (en) | 2017-04-26 |
AU2015276899B2 (en) | 2021-08-12 |
WO2015196064A1 (en) | 2015-12-23 |
US20170138946A1 (en) | 2017-05-18 |
EP3158086A4 (en) | 2018-01-10 |
JP6684230B2 (ja) | 2020-04-22 |
AU2015276899A1 (en) | 2017-01-05 |
EA201692497A1 (ru) | 2017-06-30 |
IL249443B (en) | 2022-05-01 |
JP2017525337A (ja) | 2017-09-07 |
EA036889B1 (ru) | 2021-01-12 |
ES2870096T3 (es) | 2021-10-26 |
SG11201610610YA (en) | 2017-01-27 |
CA2952285A1 (en) | 2015-12-23 |
ZA201608555B (en) | 2022-05-25 |
IL249443A0 (en) | 2017-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112016029911A2 (pt) | biomarcadores para resposta a inibidores de ezh2 | |
BR112017009159A2 (pt) | métodos e biomarcadores para predizer a eficácia e avaliação de um tratamento com agonista de ox40 | |
BR112017001677A2 (pt) | biomarcadores para predizer resposta de dlbcl ao tratamento com um inibidor de btk | |
BR112018002040A2 (pt) | controle de uma nuvem de dispositivo | |
CL2016000400A1 (es) | Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub-aguda o crónica. | |
BR112018003885A2 (pt) | método e sistema para estimar a porosidade associada à matéria orgânica, método para avaliar o potencial de produção de um poço ou formação, e, meio legível por computador não transitório | |
BR112017006805A2 (pt) | método implementado por computador, instruções de armazenamento em meio legível por computador não transitório e sistema de computador | |
BR112017017152A2 (pt) | fluxo contínuo de vídeo de baixa latência | |
BR112017000790A2 (pt) | métodos e dispositivos para controle do tamanho de bolhas enfisematosas | |
BR112016016101A2 (pt) | Métodos para determinar o estado do distúrbio inflamatório, para monitorar a progressão de uma doença inflamatória ou monitorar a eficácia de um tratamento, kit, e, uso da determinação da presença, ou do nível, de tesnacina-c citrulinada e/ou um ou mais fragmentos de tesnacina-c citrulinada e/ou de autoanticorpos com especificidade para os mesmos | |
BR112017017345A2 (pt) | camadas de metal para uma célula de bit de três portas | |
BR112016025627A2 (pt) | biomarcadores e combinações dos mesmos para diagnóstico de tuberculose | |
MX2015015605A (es) | Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib. | |
BR112016026264A2 (pt) | sistema e método dos mesmos para otimizar o tempo de inicialização de computadores com múltiplas cpus. | |
BR112015017403A2 (pt) | biomarcadores de terapia de combinação de anti-tnf e anti-il17 para doença inflamatória | |
MA40998A (fr) | Thérapies contre une envenimation, ainsi que compositions, systèmes et kits pharmaceutiques associés | |
BR112016026544A2 (pt) | métodos para inibir a necroptose | |
IL278967A (en) | Biomarkers to determine the efficacy of immune checkpoint inhibitors | |
BR122020014835A8 (pt) | Método de inspeção de objetos | |
BR112017007068A2 (pt) | ?método para operar um medidor de fluxo, e, medidor de fluxo? | |
EA201792641A1 (ru) | Ингибитор оси igfbp3/tmem219 и диабет | |
BR112018008749A8 (pt) | métodos de detecção de apolipoproteína | |
BR112017010005A2 (pt) | aparelho e método para considerar localidade espacial no carregamento de elementos de dados para execução | |
BR112017024765A2 (pt) | aparelho para determinar um mapa de profundidade para uma imagem, método para determinar um mapa de profundidade para uma imagem, e produto de programa de computador | |
BR112018067851A2 (pt) | composições e métodos para o tratamento de artrite reumatoide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C12Q 1/68 , G01N 33/68 , G01N 33/574 Ipc: G01N 33/68 (2006.01), C12Q 1/68 (2018.01), G01N 33 |
|
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |